N-terminal and core-domain random mutations in human topoisomerase II α conferring bisdioxopiperazine resistance  by Jensen, Lars H et al.
N-terminal and core-domain random mutations in human topoisomerase
II K conferring bisdioxopiperazine resistance
Lars H. Jensena;b;*, Irene Wessela, Marianne MÖllera, John L. Nitissc, Maxwell Sehesteda,
Peter B. Jensenb
aDepartment of Pathology, Laboratory Center, Righospitalet 5444, Frederik V’s Vej 11, DK-2100, Copenhagen, Denmark
bLaboratory for Experimental Medical Oncology, Finsen Center, Righospitalet 5074, DK-2100 Copenhagen, Denmark
cDepartment of Molecular Pharmacology, St. Jude Children’s Research Hospital, Memphis, TN 38101, USA
Received 28 June 2000; revised 1 August 2000; accepted 1 August 2000
Edited by Horst Feldmann
Abstract Random mutagenesis of human topoisomerase II K
cDNA followed by functional expression in yeast cells lacking
endogenous topoisomerase II activity in the presence of ICRF-
187, identified five functional mutations conferring cellular
bisdioxopiperazine resistance. The mutations L169F, G551S,
P592L, D645N, and T996L confer s 37, 37, 18, 14, and 19 fold
resistance towards ICRF-187 in a 24 h clonogenic assay,
respectively. Purified recombinant L169F protein is highly
resistant towards catalytic inhibition by ICRF-187 in vitro while
G551S, D645N, and T996L proteins are not. This demonstrates
that cellular bisdioxopiperazine resistance can result from at
least two classes of mutations in topoisomerase II; one class
renders the protein non-responsive to bisdioxopiperazine com-
pounds, while an other class does not appear to affect the
catalytic sensitivity towards these drugs. In addition, our results
indicate that different protein domains are involved in mediating
the effect of bisdioxopiperazine compounds. ß 2000 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
Type II topoisomerase is a family of highly conserved nu-
clear enzymes capable of transferring one DNA double helix
through a transient double strand break in another DNA
double helix [1]. The importance of this unique mechanistic
action which is absolutely required in chromosome segrega-
tion following cell division is illustrated by the fact that all
living cells possess topoisomerase II enzymes. Higher verte-
brates including humans express two isoforms of topoisomer-
ase II; a 170 kDa K isoform mainly found in proliferating
cells where its expression is highest in the G2/M phase of
the cell cycle, and a 180 kDa L isoform found in both pro-
liferating and non-proliferating cells whose expression is in-
dependent of the cell cycle status [2].
Besides being an essential enzyme human topoisomerase II
is also an important target in cancer therapy. One major class
of anti-cancer drugs acts by stabilizing a transient con¢gura-
tion of topoisomerase II, where the enzyme is covalently at-
tached to DNA [3]. These are referred to as cleavable complex
stabilizing drugs and are represented by such clinically impor-
tant compounds as the anthracyclines (doxorubicin, dauno-
rubicine), the epipopdohyllotoxins (VP-16, VM-26), and the
aminoacridines (m-AMSA). Another major class of drugs
are catalytic inhibitors of topoisomerase II exempli¢ed by
merbarone and aclarubicin which do not induce DNA breaks
[4].
Bisdioxopiperazines are topoisomerase II-directed drugs
which lock topoisomerase II as a closed clamp on DNA by
stabilizing an otherwise transient N-terminal dimer interaction
formed upon ATP binding [5]. These drugs are also known to
inhibit the ATPase activity of topoisomerase II enzymes [6].
Originally classi¢ed as catalytic inhibitors believed to exert
their cytotoxic e¡ect through inhibition of decatenation activ-
ity [7,8], recent data indicate that the bisdioxopiperazine com-
pounds kill cells through the formation of non-covalent closed
clamp complexes in vivo interfering with basic DNA metabol-
ic processes resulting in more rapid and pronounced cell death
than seen by inhibition of enzymatic activity [9,10]. Although
much information concerning mechanistic and thermodynam-
ic properties of topoisomerase II trapped on DNA in the
presence of bisdioxopiperazine analogues has emerged during
recent years [6,11^13], the connection between the action of
these on topoisomerase II and cytotoxicity has been less in-
vestigated.
In order to study the mechanism of bisdioxopiperazine-
mediated cell killing, we have used a random mutagenesis
protocol to generate cellular bisdioxopiperazine resistance
mediated through mutations in human topoisomerase II K.
2. Materials and methods
2.1. Constructs
The expression vector for human topoisomerase II K in yeast pMJ1
[14] comprises the entire coding region of human topoisomerase II K
under control of a constitutive yeast topoisomerase I promoter, an
URA3 selectable marker, a yeast origin of replication and a yeast
centromere sequence for the introduction and maintenance in yeast
cells. The plasmid pYX113hTOPII [15] comprises the same functions
as pMJ1, but in this construct the expression of human topoisomerase
II K is controlled by an galactose inducible GAL-1 promoter.
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2.2. Yeast strains
The hyper-permeable temperature sensitive and RAD52 de¢cient
yeast strain JN394t2-4 (MATa, ura52, leu2, trp1, his7, ade1-2, ISE2,
rad52: :LEU2, top2-4) [14] was used for the isolation of bisdioxopi-
perazine resistance conferring mutations, in clonogenic assays and for
the assessment of topoisomerase II decatenation activity in crude ex-
tracts. The protease de¢cient topoisomerase I negative yeast strain
JelvTop1 (trp1, leu2, ura-52, pbr-1122, pep4-3, vhis3: :PGAL10-
GAL4, TOP1: :LEU2) [15] was used for the over expression of wild
type (wt) and mutant human topoisomerase II K to be subsequently
puri¢ed.
2.3. Drugs
ICRF-187 (Cardioxane; Chiron) was dissolved in sterile H2O at 50
mg/ml just prior to use. ICRF-193 a kind gift from Dr. Donald
Witiak, University of Wisconsin (WI, USA) was dissolved in
DMSO at 10 mg/ml. VP-16 (Etoposide; Bristol-Myers) was purchased
ready for infusion and was not diluted further. m-AMSA (Parke-Da-
vis) was diluted in DMSO to 10 mg/ml and merbarone (kindly pro-
vided by The Drug Synthesis Chemistry Branch, Development Ther-
apeutics Program, Division of Cancer Treatment and Diagnostics,
National Cancer Institute, Bethesda, MD, USA), was dissolved in
DMSO at 10 mg/ml.
2.4. In vitro mutagenesis of plasmid DNA
20 Wg supercoiled pMJ1 plasmid DNA was added to 1 ml reaction
mixture consisting of 1 M hydroxylamine (Sigma), 100 mM NaCl and
100 mM sodium pyrophosphate, pH = 7.0. The reaction mixture was
incubated at 75‡C for 1 h. After desalting, 200 ng mutagenized plas-
mid DNA was transformed into competent TOP10 Escherichia coli
cells (Invitrogen) which resulted in approximately 20 000 transformed
bacterial colonies which were pooled and grown for 9 h with selection
in 300 ml LB medium. Plasmid DNA was isolated using a tip 500
Quia¢lter plasmid puri¢cation kit (Qiagen) and used to transform
JN394t2-4 cells.
2.5. Isolation of ICRF-187 resistant clones
Yeast cells were transformed using a modi¢ed lithium acetate pro-
tocol with single-stranded DNA as carrier. Cells were plated to gen-
erate approximately 500 colonies per 100 mm petri dish. A total of
approximately 20 000 yeast colonies were obtained on selective syn-
thetic medium lacking uracil (SC3URA) plates at the permissive tem-
perature of 25‡C. 7 days after transformation the SC3URA plates
were replica-plated onto complete medium containing yeast extract,
peptone, dextrose and adenine (YPDA) plates containing 75 WM
ICRF-187 which were incubated at the non-permissive temperature
35‡C for 72 h to score resistant clones. For each resistant clone a 100
ml culture grown overnight at 34‡C in YPDA medium was used for
the isolation of plasmid DNA.
2.6. Rescue of plasmid DNA from ICRF-187 resistant cells
Plasmid DNA was isolated from 100 ml cultures grown to satura-
tion as described in [16].
2.7. Sequencing of human topoisomerase II K cDNA
Human topoisomerase II K cDNA in recovered pMJ1 plasmids was
sequenced using a set of primers described previously [17]. Sequencing
was performed using a dRhodamine Terminator Cycle Sequencing kit
(Perkin Elmer) as described by the manufacturer. Cycle sequencing
was performed using a Perkin Elmer GeneAmp 2400 thermocycler.
Samples were analyzed using an ABI PRISM 377 sequencer.
2.8. Reconstruction of ICRF-187 conferring mutations
Identi¢ed mutations were reconstructed in pMJ1 and pYX113hTO-
PII by oligo nucleotide-directed mutagenesis using a Quick change
site-directed mutagenesis kit (Stratagene) as previously described
[17] using the mutagenic primers depicted in Table 1. The presence
of reconstructed mutations was veri¢ed by sequencing as described
above.
2.9. Determination of drug sensitivity in vivo
Overnight cultures of cells in log phase were diluted to 2U106 cells/
ml in pre-warmed YPDA medium, and 3 ml cultures were exposed to
di¡erent concentrations of VP-16, m-AMSA, ICRF-187, and ICRF-
193 for 24 h, 200 rpm, 34‡C. 1 ml samples removed after 0 and 24 h
were washed twice in distilled sterile H2O, diluted 0^104 times in
distilled sterile H2O. Next, 200 Wl of diluted cells were plated to
SC3URA plates which were incubated for 6 days at 25‡C prior to
counting. Plates containing 200^600 colonies were used for counting.
Finally, relative cell growth after 24 h compared to 0 h was calculated
for all conditions used. All experiments were performed in duplicate.
2.10. Isolation of crude extract
Cells were grown overnight in 100 ml YPDA medium at 34‡C, 200
rpm to a density of 1^2U107 cells/ml and were harvested by centri-
fugation for 2 min at 4000 rpm, 4‡C. Isolation of crude extract was
done as described in [14].
2.11. Puri¢cation of human topoisomerase II K
The puri¢cation of wt and mutant human topoisomerase II K from
overexpressing yeast cells was carried out as described in [18].
2.12. Preparation of 3H-labeled kinetoplast DNA (kDNA)
Tritium-labeled kDNA was isolated from Crithidia fasiculata as
described in [19].
2.13. Determination of topoisomerase II decatenation activity
Decatenation of C. fasiculata kDNA was used to determine the
amount of decatenation activity in crude extract and to assess the
drug sensitivity and ATP requirement of puri¢ed mutant human topo-
isomerase II K. In experiments with puri¢ed enzyme 1 U of decate-
nation activity (de¢ned as the amount required to decatenate 200 ng
k-DNA at 37‡C in 15 min) was incubated with 200 ng kDNA and
increasing concentration of drug or ATP in a 20 Wl reaction volume at
37‡C for 15 min in topoisomerase II bu¡er (10 mM tris[hydroxy-
methyl]aminomethane (TRIS)^HCl pH = 7.9, 50 mM NaCl, 50 mM
KCl, 5 mM MgCl2, 1 mM ethylenediaminetetraacetic acid (EDTA),
15 Wg/ml bovine serum albumin (BSA) and 1 mM ATP) as described
in [17^19]. For the determination of decatenation activity in crude
extracts, increasing amounts of extract were incubated with 100 ng
kDNA for 60 min at 37‡C using the same bu¡er and reaction volume.
3. Results
3.1. Identi¢cation of mutations in human topoisomerase II K
It has previously been shown that topoisomerase II is the
target for bisdioxopiperazine compounds in yeast [20]. Fur-
ther, in two studies we have shown that mutations in topo-
isomerase II K identi¢ed in mammalian cell lines resistant
to bisdioxopiperazines conferred resistance to JN394t2-4 cells
Table 1
Primers used in oligonucleotide-directed mutagenesis
L169F-SN: GGC TAT GGA GCC AAA TTT TGT AAC ATA TC AGT
ACC
L169F-ASN: GGT ACT GAA TAT GTT ACA AAA TTT GGC TCC
ATA GCC
G551S-SN: GGT TCC CAC ATC AAA AGC TTG CTG ATT AAT
TTT ATC C
G551S-ASN: GGA TAA AAT TAA TCA GCA AGC TTT TGA TGT
GGG AAC C
P592L-SN: GGC ATT TTA CAG CCT TCT TGA ATT TGA AGA
GTG G
P592L-ASN: CCA CTC TTC AAA TTC AAG AAG GCT GTA AAA
TGC C
D645N-SN: CTG GTC CTG AAA ATG ATG CTG CTA TCA GC
D645N-ASN: GCT GAT AGC AGC ATC ATT TTC AGG ACC AG
T996L-SN: CTC CAA ACT AGT CTC ATA TGC AAC TCT ATG
GTG C
T996L-ASN: GCA CCA TAG AGT TGC ATA TGA GAC TAG TTT
GGA G
P1248L-SN: CTG AAG GAA GCC TTC AAG AAG ATG GTG TGG
P1248L-ASN: CCA CAC CAT CTT CTT GAA GGC TTC CTT CAG
The primers are presented in the 5P to 3P direction.
Nucleotides responsible for introduction of mutations in the human
topoisomerase IIK coding sequence are underlined.
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when expressed in these cells [17,18]. Transformation of
JN394t2-4 cells with mutagenized human topoisomerase II K
cDNA resulted in 13 ICRF-187 resistant colonies which were
able to grow at the non-permissive temperature in the pres-
ence of 75 WM ICRF-187. Eight resistant clones were used for
isolation of plasmid DNA. Six single base pair changes each
responsible for the change of one amino acid in the polypep-
tide chain were identi¢ed namely: G507T (L169F), G1651A
(G551S), C1778T (P592L), G1933A (D635N), C2987T
(T996L) and C3743T (P1248L). All identi¢ed mutations
were reconstructed by oligonucleotide-directed mutagenesis,
and were found to be functional except the C3743T mutation
(P1248L) which was not studied further.
3.2. In vivo drug sensitivity
24 h clonogenic assays were performed with JN394t2-4 cells
transformed with pMJ1-wt plasmid or with pMJ1 plasmids
comprising the ¢ve functional mutations L169F, G551S,
P592L, D645N and T996L. Clonogenic assay was performed
at 34‡C where human topoisomerase II K is the only active
topoisomerase II in these cells. The sensitivity of JN394t2-4
cells expressing the ¢ve mutants and wt human topoisomerase
II K towards ICRF-187, ICRF-193 and the two cleavable
complex stabilizing drugs m-AMSA and VP-16 are shown in
Fig. 1A^D, respectively. The minimal lethal concentration
(MLC) which results in a relative survival of 100% was esti-
mated from the killing curves and used to determine the rel-
ative resistance of cells expressing mutant proteins (Table 2).
3.3. Cellular bisdioxopiperazine resistance is not caused by
alterations in topoisomerase II decatenation activity
The observed ICRF-187 resistance in vivo could be caused
by altered decatenation activity in cells expressing the mutant
proteins compared to cells expressing the wt protein. To ex-
clude this possibility, decatenation activity in cells grown
under conditions equal to those used in determination of cel-
lular drug sensitivity was determined using crude extracts.
Decatenation was performed at 37‡C where endogenous yeast
topoisomerase is inactive. Of the ¢ve mutations identi¢ed only
the D645N mutation caused a signi¢cant reduction in the
decatenation activity of crude extract (Fig. 2). It can therefore
be concluded that cellular bisdioxopiperazine resistance is
generally not caused by alterations in the decatenation activity
of human topoisomerase IIK in resistant cells.
Fig. 1. Determination of drug sensitivity in clonogenic assay. JN394t2-4 cells comprising a temperature sensitive chromosomal topoisomerase II
allele were transformed with pMJ1 ^ a plasmid capable of episomal expression of human topoisomerase II K in yeast. The pMJ1 plasmid com-
prised no mutation (wt) or single base pair changes resulting in the following amino acid substitutions in the human topoisomerase II K gene
product (L169F, G551S, P592L, D645N and T996). Transformed cells were grown overnight to log phase and diluted to 2U106 cell/ml in pre-
warmed YPDA medium. The cells were incubated in the presence of di¡erent concentrations of ICRF-187 (left upper panel), ICRF-193 (right
upper panel), m-AMSA (left lower panel) and VP-16 (right lower panel) for 24 h at the non-permissive temperature and were plated to produce
200^600 viable colonies per 10 cm petri dish. Error bars represent S.E.M. of two experiments performed with individually reconstructed muta-
tions.
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3.4. In vitro drug sensitivity of puri¢ed mutant enzymes
In order to test the inhibitory e¡ect of various anti-cancer
drugs on decatenation activity wt, L169F, G551S, D645N,
and T996L proteins were puri¢ed from overexpressing yeast
cells. Puri¢ed L169F protein did not display any ICRF-187-
mediated inhibition of decatenation. In contrast, none of the
G551S, D645N and T996L proteins displayed any substantial
resistance to ICRF-187-mediated inhibition of decatenation
(Fig. 3A and Table 2). Decatenation was also carried out in
the presence of merbarone, another catalytic inhibitor of to-
poisomerase II. With merbarone the L169F protein displayed
wt sensitivity while the three core-domain mutations analyzed
D645N, G551S, and T996L all conferred some resistance (Fig.
3B and Table 2). It is also evident that the G551S and T996L
mutations which both display cross-resistance to VP-16 and
m-AMSA in clonogenic assay are resistant to inhibition of
decatenation by VP-16 (Fig. 3D and Table 2). These muta-
tions also confer reduced sensitivity to m-AMSA in the deca-
tenation assay although this is not signi¢cant (Fig. 3C).
3.5. Increased ATP requirements of mutant enzymes in
decatenation
The ATP requirement of the mutant enzymes was also as-
sessed by performing decatenation at low ATP concentra-
tions. Using this assay it is evident from Fig. 3E that the
L169F mutation increases the ATP requirement of the protein
as it is inactive at 250 WM ATP where the wt enzyme is fully
active. Surprisingly all mutations found in the core-domain of
the protein (Fig. 4) corresponding to the central part of yeast
topoisomerase II [1] also increase the ATP requirement of the
protein although to a much lesser extent.
4. Discussion
Random mutagenesis in vitro followed by functional ex-
pression in the presence of ICRF-187 identi¢ed ¢ve novel
functional mutations in the human topoisomerase II K struc-
tural gene conferring bisdioxopiperazine resistance (Fig. 4).
Four of these map to the catalytic core-domain involved in
DNA cleavage and religation while only one mutation L169F
maps to the N-terminal ATP clamp region where three pre-
viously identi¢ed mutations were found (Fig. 4) [17,18,21].
The high level of resistance towards both ICRF-187 and
ICRF-193 in vivo (Fig. 1A,B) and ICRF-187 in vitro (Fig.
3A) indicates that the L169F mutation renders the protein
non-responsive to the action of bisdioxopiperazine com-
pounds. Further, the lack of cross resistance towards the cat-
alytic inhibitor merbarone as well as the cleavable complex
stabilizing compounds VP-16 and m-AMSA indicates that the
e¡ect of the L169F mutation is speci¢c to bisdioxopiperazine
compounds. This agrees well with the location of the L169F
mutation at the N-terminal clamp region of the protein that
forms a closed clamp upon ATP binding, which is stabilized
by the bisdioxopiperazine compounds [4^6]. Also, the in-
creased requirement for ATP in decatenation ¢ts with the
location of the L169F mutation next to the Walker A ATP
binding motif 161-GXGXXG-166 (Fig. 4).
Homology alignment of human topoisomerase IIK with 46
other type 2 topoisomerases of both eukaryotic and prokary-
otic origin [22] shows that the L169F mutation maps to a
region generally displaying a high degree of conservation. In
45 of 46 cases, the residue homologous to human topoisomer-
ase II K L169 is either leucine or valine, which are both
structurally and chemically very similar. This indicates that
this residue is highly conserved among type 2 topoisomerases.
The lack of response towards bisdioxopiperazine com-
pounds in vivo and in vitro seen with the L169F protein
suggests that the L169 residue of human topoisomerase II K
may be involved in drug binding. A previously described mu-
tation changing Y50 to phenylalanine also results in complete
lack of response to bisdioxopiperazine compounds [17]. Inter-
estingly, the two homologous residues in the structure of
Fig. 2. Determination of catalytic topoisomerase II decatenation ac-
tivity in crude extract isolated from JN394t2-4 cells expressing wt
human topoisomerase II K or mutant L169F, G551S, P592L,
D645N and T996L from the pMJ1 vector. Cells were grown under
the same conditions used in clonogenic assay. Increasing amounts
of crude extract were incubated with 100 ng C. fasiculata kDNA in
20 Wl topoisomerase II reaction bu¡er at 37‡C for 60 min. Next,
catenated substrate DNA left unprocessed was separated from deca-
tenated mini circles by gel electrophoresis and visualized by ethid-
ium bromide staining. Finally, the speci¢c decatenation activity of
the crude extracts was determined as ng kDNA fully decatenated
per Wg protein per hour. Error bars represent S.E.M. of ¢ve experi-
ments using individually prepared crude extracts.
Table 2
Drug sensitivity in vivo and in vitro
Mutation MLC in 24 h clonogenic assay (WM)/relative resistance (fold) IC50 values in decatenation assay (WM)
ICRF-187 ICRF-193 m-AMSA VP-16 ICRF-187 merbarone m-AMSA VP-16
None 3.0 0.3 0.35 13.0 15 45 45 90
L169F 112 (s 37) s 10.6 (s 35) 0.15 (0.4) 20.5 (1.6) s 1500 35 42 130
G551S 112 (37) s 10.6 (s 35) 1.30 (3.7) 35.0 (2,7) 15 s 200 65 s 200
P592L 54 (18) 2.0 (7) 0.80 (2.3) 35.0 (2.7) nd nd nd nd
D645N 41 (14) 1.5 (5) 0.35 (1.0) 16.0 (1.2) 15 100 40 70
T996L 58 (19) 2.5 (8) 1.60 (4.6) s 35.0 (s 2.7) 25 s 200 50 s 200
The MLC is de¢ned as the drug concentration resulting in no cell growth and no cell killing i.e. 100% relative survival.
Relative resistance is de¢ned as MLC-mutant/MLC-wt.
nd: not determined.
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E. coli gyrase B [23] Y26 and V122 are in close proximity
suggesting that they may both contribute to a drug binding
site. However, it is important to note that E. coli gyrase does
not display sensitivity to bisdioxopiperazine compounds [11].
The fact that the human topoisomerase IIK L169 residue is
so highly conserved among type 2 topoisomerases suggests
that this residue contributes to protein function, which is con-
¢rmed in this study by the increased ATP requirement of the
L169F protein in decatenation (Fig. 3E). The functional im-
portance of this residue makes it possible that the L169F
mutation destabilizes the closed clamp which might per se
be su⁄cient to cause bisdioxopiperazine resistance. Due to
the complete lack of drug response seen with the L169F mu-
tation, we favor the drug binding hypothesis. In any case our
results strongly suggest that the N-terminal ATP-operated
clamp is a signi¢cant target for bisdioxopiperazine com-
pounds. This is supported by data from Olland and Wang
who found that ATP hydrolysis catalyzed by a N-terminal
fragment of yeast topoisomerase II constituting this protein
region (amino acid 1^409) is inhibited by ICRF-193 [13].
The core-domain mutations G551S, P592L, D645N and
T996L display a quite di¡erent phenotype. These mutations
confer less cellular bisdioxopiperazine resistance than the
Y50F [17] or L169F (Fig. 1A,B) mutations. The level of cel-
lular bisdioxopiperazine resistance conferred by these core-
domain mutations and a previously described R162Q muta-
Fig. 3. Assessment of drug sensitivity and ATP dependence with puri¢ed mutant proteins. 1 U of puri¢ed wt, L169F, G551S, D645N, or
T996L protein was incubated with 200 ng of 3H-labeled C. fasiculata kDNA in 20 Wl topoisomerase II reaction bu¡er for 15 min at 37‡C at in-
creasing concentrations of ICRF-187 (A), merbarone (B), m-AMSA (C), VP-16 (D) or at varying ATP concentrations (E). Experiments assess-
ing the drug sensitivity were performed at 1 mM ATP. Unprocessed substrate kDNA was separated from decatenated mini circles as described
in Fig. 2 and were cut out of the agarose gel and subjected to liquid scintillation counting. Finally, the amount of radioactivity expressed as
CPM was plotted against drug or ATP concentration to reveal dose response curves. Error bars represents S.E.M. of three independent experi-
ments.
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tion [18] are similar. In addition, no substantial resistance
towards ICRF-187-mediated inhibition of decatenation is ob-
served in vitro with puri¢ed core-domain mutant proteins
(Fig. 3A), which was also the case with puri¢ed R162Q pro-
tein [18]. Since the cellular bisdioxopiperazine resistance con-
ferred by these mutations is not caused by altered decatena-
tion activity in the presence of bisdioxopiperazines, the
activity of these mutant proteins must be changed in other
ways.
Among the four core-domain mutations analyzed, G551S
has the highest in vivo bisdioxopiperazine resistance. Align-
ment of human topoisomerase IIK with 44 other type 2 top-
oisomerases of both eukaryotic and prokaryotic origin [22]
shows a high level of conservation of the residues surrounding
human topoisomerase IIK G551 in general. The residue ho-
mologous to human topoisomerase IIK G551 is conserved in
17 of 17 other eukaryotic type 2 topoisomerases while 0 of 29
prokaryotic topoisomerases display glycine at the homologous
position [22]. It is thus interesting that eukaryotic type 2 topo-
isomerases which are sensitive to bisdioxopiperazine com-
pounds all have glycine at this position while this is never
the case with prokaryotic type 2 topoisomerases which are
insensitive [11]. It has been demonstrated that a core-domain
fragment of Drosophila topoisomerase II lacking the N-termi-
nal 406 amino acids as well as the C-terminal 240 amino acids
can form a closed clamp on DNA in the presence of ICRF-
159 suggesting the existence of a BPBP clamp in type II topo-
isomerases [12]. Another biochemical study also suggests
that residues in the BP region (residue 409^681) of yeast topo-
isomerase II are involved in mediating monomer^monomer
interactions [13]. In the Berger and Wang structure [1] of yeast
topoisomerase II, residues L551, L557, and Y602 which are
homologous to L565, L570, and Y612 in human topoisomer-
ase IIK play an important role mediating BPBP interactions
between the monomers [1], and alignment analysis shows
that only conservative substitutions are allowed at these posi-
tions [22]. Further, in the structure of yeast topoisomerase II
the residue homologous to human topoisomerase IIK G551,
which is G537 is in close proximity to both L551 and L557
indicating that this residue may be important for the stability
of the BPBP clamp. The high level of homology in this protein
region suggests that this may also be the case in human topo-
isomerase IIK. If so, the G551S mutation could a¡ect the
stability of the BPBP interaction.
We have previously presented data, which strongly suggests
a model, where bisdioxopiperazine compounds elicit their cy-
totoxic e¡ect primarily through the stabilization of human
topoisomerase IIK closed clamp complexes on DNA in vivo
[10]. One consequence of this model is that cellular bisdioxo-
piperazine sensitivity is expected to correlate positively to the
level of catalytic activity in cells expressing human topoiso-
merase IIK which has been shown experimentally [9]. There-
fore, any mutation causing reduced catalytic activity will con-
fer cellular bisdioxopiperazine resistance per se. Another
important consequence of this model is that mutations which
destabilizes the BPBP clamp could also result in cellular bis-
dioxopiperazine resistance without a¡ecting the catalytic sen-
sitivity of topoisomerase II in decatenation assay. It is then
possible that the G551S mutation identi¢ed in the present
study causes cellular resistance via the latter mechanism.
The P592L mutation also maps to the BP part of human
topoisomerase IIK but this mutation falls within a region of
less conserved homology than the L169F and G551S muta-
tions and the P592 residue is not conserved among 18 eukary-
otic type 2 topoisomerases aligned in [22]. In the Berger and
Wang structure the homologous yeast residue P582 proxi-
mates Y602 which is also involved in mediating BPBP dimer
interactions. It is then possible that the P592L mutation af-
fects the stability of the BPBP clamp causing cellular bisdioxo-
piperazine resistance as described above, although the P592L
protein has not been characterized in vitro.
The D645N mutation also falls within a region of limited
sequence homology to other type 2 topoisomerases, however
the D645 residue is well conserved among 18 eukaryotic type
2 topoisomerases aligned in [22]. The homologous residue in
yeast topoisomerase II D635 is not resolved in the Berger and
Wang structure and is probably part of the linker region
which connects the BP and AP part of the protein [1]. Clearly,
the function of this linker region must be important for pro-
tein function which is also suggested by the fact that the
D645N protein displays reduced decatenation activity (Fig.
2). It is possible that this reduction in enzymatic activity is
su⁄cient to cause bisdioxopiperazine resistance. Alternatively,
the D645N mutation may a¡ect the stability of the closed
clamp leading to resistance as described above.
The T996L mutation maps to a region of human topoiso-
merase II K which has only limited sequence homology to
other eukaryotic type 2 topoisomerases [22]. Also, this muta-
tion maps to the gyr A homology part of the core-domain and
is localized very distant to parts in the three dimensional
protein structure involved in forming the N-terminal clamp(s)
[1]. Instead this mutation maps to the vicinity of the C-termi-
nal dimerization region of the protein [1,24]. According to the
two gate mechanism of strand passage [25,26], the G-segment
exits through the N-terminal gate which makes it di⁄cult to
explain how the T996L mutation can a¡ect bisdioxopipera-
zine action. It is also noteworthy that the T996L mutation
results in a drug resistance pro¢le very similar to the G551S
mutation even though these mutations map to very di¡erent
parts of the protein (Figs. 1 and 3).
In summary we conclude that cellular bisdioxopiperazine
resistance can result from at least two classes of mutations;
(i) mutations that render the protein non-responsive to these
drugs (Y50F and L169F) and (ii) mutations which do not
a¡ect the catalytic sensitivity towards these drugs in decate-
nation (R162Q, G551S, D645N and T996L). In addition, our
Fig. 4. Schematic linear presentation of human topoisomerase II K
showing the N-terminal ATP-operated clamp which is believed to
capture the transfer-DNA (T-DNA) segment upon ATP binding,
the catalytic core-domain, which is involved in the cleavage and re-
ligation of the gate-DNA (G-DNA) segment and the hyper variable
region. The Walker A and Walker B ATP binding motives and the
Y805 active site tyrosine are also shown. The L169F, G551S,
P592L, D645N, and T996L mutations are all identi¢ed in the
present study while the underlined T49I, Y50F, and R162Q muta-
tions were previously identi¢ed in mammalian cell lines selected for
bisdioxopiperazine resistance [18,19,22].
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results indicate that di¡erent protein domains are involved in
mediating the e¡ect of the bisdioxopiperazine compounds.
Acknowledgements: The technical assistance of Sanne Christiansen
and Anette Nielsen is highly valued. Supported by the Danish Cancer
Society, the Novo Nordisk Foundation and the H:S Research Coun-
cil. J.L.N. was supported by NCI, National Institutes of Health,
Grants CA52814 and CA21765 and by funds from the American
Lebanese Syrian Associated Charities (ALSAC).
References
[1] Berger, J.M., Gamblin, S.J., Harrison, S.C. and Wang, J.C.
(1986) Nature 379, 225^232.
[2] Grue, P., Gra«sser, A., Sehested, M., Jensen, P.B., Ushe, A.,
Straub, T., Ness, W. and Boege, F. (1998) J. Biol. Chem. 273,
33660^33666.
[3] Chen, A.Y. and Lui, L.F. (1994) Annu. Rev. Pharmaco. Toxicol.
34, 191^218.
[4] Andoh, T. and Ishida, R. (1998) Biochim. Biophys. Acta 1400,
155^171.
[5] Roca, J., Ishida, R., Berger, J.M., Andoh, T. and Wang, J.C.
(1994) Proc. Natl. Acad. Sci. USA 91, 1781^1785.
[6] Morris, K.S., Baird, C.L. and Lindsley, J.E. (2000) J. Biol.
Chem. 275, 2613.
[7] Tanabe, K., Ikegami, Y., Ishida, R. and Andoh, T. (1991) Cancer
Res. 51, 4903^4908.
[8] Ishida, R., Miki, T., Narita, T., Yui, R., Sato, M., Utsumi, K.R.,
Tanabe, K. and Andoh, T. (1991) Cancer Res. 51, 4909^4916.
[9] van Hille, T. (1998) Cancer Chemother. Pharmacol. 42, 345^356.
[10] Jensen, L.H., Nitiss, K.C., Rose, A., Dong, J., Zhou, J., Hu, T.,
Oshero¡, N., Jensen, P.B., Sehested, M. and Nitiss, J.L. (2000)
J. Biol. Chem. 275, 2137^2146.
[11] Sato, M., Ishida, R., Narita, T., Kato, J.I., Ikeda, H., Frkazawa,
H. and Andoh, T. (1997) Biochem. Pharmacol. 54, 545^550.
[12] Chang, S. and Hu, T. (1998) J. Biol. Chem. 273, 19822^19828.
[13] Olland, S. and Wang, J.C. (1999) J. Biol. Chem. 274, 21688^
21696.
[14] Hsiung, Y., Jannatpour, M., Rose, A., McMahon, J. and Nitiss,
J.L. (1996) Cancer Res. 56, 91^99.
[15] Nitiss, J.L., Zhou, J., Rose, A., Hsiung, Y., Gale, K.C. and
Oshero¡, N. (1998) Biochemistry 37, 3078^3085.
[16] Strathern, J.N. and Higgins, D.J. (1991) Methods Enzymol. 194,
319^329.
[17] Sehested, M., Wessel, I., Jensen, L.H., Holm, B., Oliver, R.S.,
Kenwrick, S., Crighton, A.M., Nitiss, J.L. and Jensen, P.B.
(1998) Cancer Res. 58, 1460^1468.
[18] Wessel, I., Jensen, L.H., Jensen, P.B., Falck, J., Rose, A., Roerth,
M., Nitiss, J.L. and Sehested, M. (1999) Cancer Res. 59, 3442^
3450.
[19] Sahai, B.M. and Kaplan, J.G. (1986) Anal. Biochem. 156, 364^
379.
[20] Ishida, R., Hamatke, M., Wassermann, R.A., Nitiss, J.L. and
Wang, J.C. (1995) Cancer Res. 55, 2299^2303.
[21] Yalowich, J.C., Thampatty, P., Allan, W.P., Chee, G. and Hasin-
o¡, B.B. (1998) Proc. Am. Assoc. Cancer Res. 39, 375.
[22] Caron, P.R. (1999) DNA topoisomerase protocols, DNA topol-
ogy and enzymes, in: Methods in Molecular Biology vol. 94
(Bjornsti, M.A. and Oshero¡, N., Eds.), pp. 279^316, Humana,
Totowa. NJ.
[23] Wigley, B.D., Davies, G.J., Dodson, E.J., Maxwell, A. and Dod-
son, G. (1991) Nature 351, 624^629.
[24] Bjergb×k, L., Jensen, S., Westergaard, O. and Andersen, A.H.
(1999) J. Biol. Chem. 274, 26529^26536.
[25] Roca, J. and Wang, J.C. (1992) Cell 71, 883.
[26] Roca, J. and Wang, J.C. (1994) Cell 77, 609^616.
FEBS 24047 28-8-00
L.H. Jensen et al./FEBS Letters 480 (2000) 201^207 207
